Failure of isoniazid chemoprophylaxis during infliximab therapy [4]

Emerging Infectious Diseases

Volumn 13, Issue 9, 2007, Pages 1428-1429

  Fernández Guerrero, Manuel L ^a,b   Esteban, Jaime ^a   Acebes, Carlos ^a   Górgolas, Miguel ^a  

^a UNIVERSITY OF MADRID   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN;

ADULT; ANKYLOSING SPONDYLITIS; BACTERIAL INFECTION; BACTERIUM ISOLATE; CASE REPORT; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HUMAN; LETTER; LUNG INFECTION; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

EID: 34848849604     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1309.070070     Document Type: Letter

References (10)

1. Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis. 2005;64(Suppl 4):S65-9.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5.
3. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-55.
4. Pfyffer GE, Brown-Elliott BA, Wallace RJ. Mycobacterium: general characteristics, isolation, and staining procedures. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington: ASM Press; 2003;532-59.
5. Carmona L, Gómez-Reino JJ, Rodríguez V, Montero D, Pascual E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52:1766-72.
6. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003;29:2327-9.
7. Alcaide F, Calatayud L, Santia M, Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin and four conventional drugs against Mycobacterium kansasii. Antimicrob Agents Chemother. 2004;48:4562-5.
8. Shitrit D, Baum GL, Priess R, Lavy A, Shitrit AB, Raz M, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129:771-6.
9. Sun Z, Zhang Y. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob Agents Chemother. 1999;43:537-42.
10. American Thoracic Society and Centers for Disease Control. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-47.